Curis, Inc. (NASDAQ:CRIS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Several other brokerages have also recently weighed in on CRIS. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub lowered shares of Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $5.50.

Shares of Curis (NASDAQ CRIS) traded up 1.26% on Tuesday, reaching $1.61. 1,365,612 shares of the company’s stock were exchanged. Curis has a 12 month low of $1.47 and a 12 month high of $3.72. The company’s market cap is $231.64 million. The firm’s 50-day moving average price is $1.79 and its 200 day moving average price is $2.04.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business had revenue of $2.10 million during the quarter, compared to analyst estimates of $2.08 million. During the same quarter last year, the company posted ($0.09) earnings per share. The company’s revenue was up 23.5% on a year-over-year basis. Equities research analysts predict that Curis will post ($0.40) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Curis, Inc. (CRIS) Downgraded by Zacks Investment Research” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/10/03/curis-inc-cris-downgraded-by-zacks-investment-research.html.

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in shares of Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 13,448 shares during the period. Prudential Financial Inc. bought a new stake in Curis during the first quarter worth about $105,000. OxFORD Asset Management LLP bought a new stake in Curis during the second quarter worth about $115,000. Dynamic Technology Lab Private Ltd lifted its position in Curis by 22.3% during the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 7,638 shares during the period. Finally, Voya Investment Management LLC lifted its position in Curis by 21.8% during the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 12,207 shares during the period. Hedge funds and other institutional investors own 44.72% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.